anticancer agent

Triglycidyl isocyanurate (Teroxirone) 是一种三氮烯三环氧化合物，可通过 p53的激活抑制非小细胞肺癌细胞的生长。它诱导细胞凋亡，具有抗血管生成和抗肿瘤活性，用于癌症研究。

Anticancer agent 3 (Compound 4) is a anti-cancer agent.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 具有抗真菌和抗结核活性。

Anticanceragent 260 (Compound 3g 4d) 是一种口服有效的抗癌剂，能够抑制癌细胞 HCT-116、MIA-PaCa2 和 MDA-MB231 的增殖，其 IC50 分别为 98.7、81.0 和 77.2 µg mL。Anticancer agent 260 还具有促进溃疡形成、脂质过氧化的作用，同时表现出抗炎和镇痛活性。

Anticanceragent 263 (compound 7) 是一种有效的抗癌剂，与 G-四链体 DNA (G4) 序列 22-mer Pu22 (c-MycDNA 的模拟物) 结合。作为结构调节剂，它显著增强蛋白质 α-螺旋的形成，并具备构建超分子网络的能力，同时不具有细胞毒性。

Anticanceragent 257 (compound of formula (I)) 是一种抗癌剂，具有调节Nur77和Nurr1的功能。

Anticanceragent 266 (Compound 3B) 是一种用于抑制肿瘤细胞增殖的抗癌剂，对 MCF-7 乳腺癌细胞系的 IC50 为 0.13 μM。

Anticancer agent 7 (Example 5) is an anti-cancer agent that exhibits potent anticancer activity against H1650 lung cancer cells, with an IC50 value of 5 μM.

Anticancer agent 11 an effective broad-spectrum anticancer agent, exerts its therapeutic potential by suppressing angiogenesis and facilitating the formation of DNA cross-links.

Anticancer agent 15, an anticancer agent, exerts its efficacy by elevating intracellular levels of reactive oxygen species (ROS) and inducing cell death in melanoma cancer cells through necroptosis.

Anticancer agent 13 is an anticancer agent from dicarboxylic acids and amines.

Anticancer agent 38 (compound 19) 是芳基脲化合物，是一种有效的抗癌剂。Anticancer agent 38 抑制 A431 细胞生长的 IC50为 5.2 μg mL。

Anticancer agent 68 is (Compound 12) 是一种抗癌剂。Anticancer agent 68 将细胞阻滞在 G2 M 期并诱导程序性细胞死亡。Anticancer agent 68 通过激活 p53 和 PTEN 诱导上调肿瘤抑制。

Anticancer agent 75 具有良好的抗疟原虫活性。Anticancer agent 75 是有效的抗癌剂，在癌细胞系中表现出细胞毒性和选择性。Anticancer agent 75 对正常人肾细胞系的细胞毒性比阿霉素标准品至少低 35 倍。

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0 G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 30 (compound 6f-Z) is a potent anticancer compound. It belongs to the class of 3-arylidene-2-oxindole derivatives and acts as a selective inhibitor of CDK2. Extensive research has demonstrated its significant anticancer activity, making it a promising candidate for cancer treatment [1].

Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities and inducing apoptosis as well as cell cycle arrest at G0 G1 phase. Moreover, Anticancer agent 47 has exhibited significant in vivo antitumor activities [1].

Anticancer agent 37 (compound 18) is a sulfonylurea derivative known for its potent anticancer activity. It efficiently inhibits the growth of HePG2 cells, displaying an IC 50 value of 17.2 μg mL [1].

Anticancer agent 83 是一种强效抗癌剂，抑制 LOX IMVI 细胞生长的 GI50为 0.15 mM。Anticancer agent 83 能够降低线粒体膜电位，并诱导 DNA 损伤，以诱导白血病细胞凋亡 (apoptosis)。

Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].

Anticancer agent 35 (compound 10) 是一种磺酰脲类衍生物，一种有效的抗癌剂。Anticancer agent 35 抑制 A549、A431、PACA2 细胞生长，IC50分别为 18.1 μg mL、4.0 μg mL、18.9 μg mL。

Anticancer agent 56 (compound 4d) is a powerful anti-cancer compound with favorable drug-like properties. It shows significant anticancer activity against multiple cancer cell lines, with an IC50 value of less than 3 μM. Anticancer agent 56 exerts its effects by causing cell cycle arrest at the G2 M phase and activating the mitochondrial apoptosis pathway. Mechanistically, it induces the accumulation of reactive oxygen species (ROS), upregulates BAX, downregulates Bcl-2, and triggers the activation of caspases 3, 7, and 9 [1].

Anticancer agent 82 是 FiVe1 衍生物，是一种口服有效的选择性抗癌剂。FiVe1 能够结合 III 型中间丝蛋白vimentin(VIM)，诱导 Ser56 过度磷酸化，导致有丝分裂的选择性中断和转化表达 VIM 的间充质癌细胞的多核化。Anticancer agent 82 比 FiVe1 表现出更好的口服利用度和药代动力学特征。